Neonatal Respiratory Distress Syndrome (NRDS)

Last updated: March 31, 2026

Neonatal respiratory distress syndrome (NRDS) is the most common cause of respiratory distress in preterm neonates. It is caused by insufficient surfactant production at < 34 weeks of gestation.

Antenatal steroids reduce the risk of neonatal respiratory distress syndrome by 40%.

  • Predisposing factors
    • Prematurity
      • < 34 weeks of gestation, especially < 28 weeks
    • Maternal diabetes – delayed surfactant due to fetal hyperinsulinism
    • Perinatal asphyxia – hypoxia impairs surfactant production
    • Caesarean section, or **precipitous delivery due to lack of stress-induced steroid surge
    • Multiple gestation, particularly the second twin
    • Cold stress
    • History of NRDS in a sibling
    • Male sex
  • Pathophysiology
    • Surfactant is produced by type II pneumocytes. Production begins at 20 – 24 weeks, and mature levels are reached at 35 weeks of gestation. Corticosteroids increase surfactant production
    • Surfactant helps to reduce alveolar surface tension and prevent atelectasis
    • In preterms < 34 weeks, surfactant synthesis is insufficient. This causes increased surface tension and atelectasis during exhalation
    • Persistent atelectasis causes endothelial damage, causing fibrin and proteins to leak into the alveoli and form a hyaline membrane
    • Atelectasis and hyaline membrane formation cause ventilation-perfusion (V/Q) mismatch, which leads to hypoxemia and cyanosis
    • Pulmonary vasoconstriction from hypoxia can worsen the ventilation-perfusion mismatch
  • Signs and symptoms
    • Respiratory distress (tachypnea, intercostal indrawing, grunting, cyanosis, flaring of nasal alae)
    • On auscultation
      • Diminished air entry
      • Basal fine crepitations
  • Antenatal investigations
    • Lecithin/sphingomyelin ratio
      • 2.5 = Mature lungs
      • 1.5-2 = Transitional lung with increased risk of RDS
      • < 1.5 = Immature lung with risk of severe RDS
    • Saturated phosphatidylcholine
      • <500 μg/dL = Immature lung with high risk of RDS
      • 500 μg/dL = Mature lung
  • Post-natal investigations
    • Chest X-ray:
      • Diffuse bilateral reticulonodular infiltrates (diffuse ground glass appearance),
      • Air bronchograms (contrast of aerated airways vs collapsed airways),
      • Small lung volumes
      • Severe RDS shows opacification of both lungs
    • Arterial blood gases:
      • Hypoxemia
      • Hypercapnia
      • Respiratory and metabolic acidosis
    • UECs
    • CBC + CRP: evaluate the possibility of early-onset NNS in a preterm baby (clinically indistinguishable from RDS)
    • Shake test: Done within one hour of life to determine the amount of surfactant present. 0.5ml of gastric aspirate + 4ml of Normal saline + 0.5ml of alcohol are mixed and shaken; check for presence of bubbles
      • Absence of bubbles – absent surfactant, hence high risk of RDS
      • Incomplete bubbles – intermediate risk of surfactant
      • Double row of bubbles or more – no risk of RDS
  • Prevention
    • Antenatal prophylaxis:
      • Betamethasone or dexamethasone is administered to mothers in preterm labor, at least 24 hrs before delivery.
      • This accelerates surfactant production.
    • Avoid risk factors
  • Supportive treatment
    • Supplemental O2 via nasal CPAP for mild cases
    • Mechanical intubation for severe cases
    • Incubator care
    • Frequent vital monitoring
    • Adequate fluids and feeds
  • Definitive treatment
    • Intubation for exogenous surfactant administration: definitive treatment. 3-5ml per kg per dose given at 6-12 hour intervals
    • Prophylactic exogenous surfactant for all neonates born ≤ 27 weeks
    • Empiric antibiotics should be given since NRDS is hard to differentiate from congenital pneumonia
  • Indications for surfactant therapy
    • FiO2 required >30%
    • Recent intubation
    • SAS score < 4

Differentiating TTN from NRDS

FeatureTransient Tachypnea of the Newborn (TTN)Neonatal Respiratory Distress Syndrome (NRDS)
PathophysiologyDelayed clearance of lung fluidSurfactant deficiency → Alveolar collapse
Gestational AgeTerm or late preterm (≥35 weeks)Preterm (<34 weeks)
Risk FactorsC-section, maternal diabetes, macrosomia, inadequate thoracic squeezePrematurity, maternal diabetes, and perinatal asphyxia
Onset of SymptomsWithin hours after birthImmediately after birth
Respiratory RateTachypnea (>60 bpm)Tachypnea (>60 bpm)
Oxygen RequirementMinimal, resolves in 24-72 hoursProgressive hypoxia needs CPAP or mechanical ventilation
Chest radiograph FindingsHyperinflation, fluid in fissures, perihilar streakingGround-glass opacities, air bronchograms, and low lung volume
TreatmentSupportive (O₂, CPAP if needed)Surfactant, CPAP, ventilation if severe
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Post Discussion

Your email address will not be published. Required fields are marked *